Condition
Antiviral Drug Adverse Reaction
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 4 (2)
Trial Status
Unknown3
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04340388Phase 4Completed
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
NCT03251144Phase 1Completed
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
NCT03775798Unknown
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
NCT03566030Unknown
Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance
NCT03296930Phase 4UnknownPrimary
Effect Of DAAs For Treatment Of HCV On Normal Kidney
Showing all 5 trials